摘要
目的:观察通脉益智丸治疗遗忘型轻度认知损害(mild cognitive impairment-amnestic,aMCI)患者的临床疗效。方法:对各组试验药进行盲法要求包装,采用随机、双盲、阳性平行对照法共观察60例aMCI患者。治疗组30例,服用通脉益智丸,每次3丸,每日3次,同时服脑复康胶囊安慰剂每次0.8g,每日3次;对照组30例,服用脑复康胶囊每次0.8g,每日3次,同时服通脉益智丸安慰剂每次3丸,每日3次,连续治疗,两组总疗程均为3个月。于服药前、服药3个月后分别进行神经心理学量表评价和脑血流、血脂检测分析。结果:与对照组相比,治疗组用药后词语即刻回忆、简易精神状态检查的成绩显著提高(P<0.05);对患者大脑前、后动脉的平均血流速度均有明显提高作用(P<0.05或P<0.01),并且显著改善脑动脉的阻力指数(P<0.01);对患者血脂的改善作用与脑复康比较差异均有统计学意义(P<0.05或P<0.01)。结论:通脉益智丸治疗遗忘型轻度认知损害有较好临床疗效,效果优于阳性对照药脑复康胶囊。
Objective： To evaluate the effect of Tongmai Yizhi Pills on patients with mild cognitive impairment-amnestic （aMCI）. Methods： The investigational drugs were packed by blind method. A randomized, double-blind and controlled trial was conducted on sixty patients with aMCI. The sixty patients were randomly divided into treatment group （n=30）, orally Tongmai Yizhi Pills, and control group （n=30）, orally Piracetam capsule, for 90 days. All subjects’cognitive function and behavior ability were assessed by memory, cerebral blood flow, blood lipids, including triglyceride （TG）, total cholesterol （TC）, low density lip oprotein cholesterol （LDL-C）, high density lip oprotein cholesterol （HDL-C）, apolip oprotein A-1 （ApoA-1） and apolip oprotein B-100 （ApoB-100）. The indexes were detected before and after the treatment. Results： Score of clinical memory scale in grouppatients was significantly higher than that of aMCI patients before treatment （P0.05）, blood flow parameters of anterior cerebral artery, posterior cerebral artery and resistant index in patients of treatment group increased significantly （P0.05,P0.01） . Tongmai Yizhi Pills significantly improved the blood lipid, such as the level of TG, LDL-C, HDL-C, ApoA-1 and ApoB-100, and better than aniracetam （P0.05,P0.01）. Conclusion： Tongmai Yizhi Pills had better therapeutic effect than piracetam capsule in mild cognitive impairment-amnestic.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2010年第4期591-594,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
江苏省中医药局科技专项资助项目(No.HZ07031)~~
